Scalper1 News
Regeneron Pharmaceuticals (REGN) reported more positive trial data on its drug Eylea a day ahead of its Q4 earnings report, when investors will be listening closely to 2014 guidance. Regeneron and its partner Bayer (BAYRY) reported that patients with diabetic macular edema (DME) continued to do well after 100 weeks on Eylea, with both monthly and bimonthly dosings. The news was not a surprise, and Regeneron stock was up just a fraction in morning Scalper1 News
Scalper1 News